216 related articles for article (PubMed ID: 36759424)
21. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
22. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
23. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.
Nanda KK; Tignor S; Clancy J; Marota MJ; Allain LR; D'Addio SM
J Pharm Sci; 2021 Dec; 110(12):3773-3775. PubMed ID: 34400183
[TBL] [Abstract][Full Text] [Related]
25. MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
Tchernev G; Kordeva S
Georgian Med News; 2023 Feb; (335):90-94. PubMed ID: 37042596
[TBL] [Abstract][Full Text] [Related]
26. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
27. Nitrosamine Impurities in Herbal Formulations: A Review of Risks and Mitigation Strategies.
Shekhar NR; Nagappan K; Singh MT; Dhanabal SP
Drug Res (Stuttg); 2023 Oct; 73(8):431-440. PubMed ID: 37487523
[TBL] [Abstract][Full Text] [Related]
28. International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines.
Keire DA; Bream R; Wollein U; Schmaler-Ripcke J; Burchardt A; Conti M; Zmysłowski A; Keizers P; Morin J; Poh J; George M; Wierer M
AAPS J; 2022 Apr; 24(3):56. PubMed ID: 35449372
[TBL] [Abstract][Full Text] [Related]
29. Tolerability of risk: A commentary on the nitrosamine contamination issue.
Elder DP; Johnson GE; Snodin DJ
J Pharm Sci; 2021 Jun; 110(6):2311-2328. PubMed ID: 33705731
[TBL] [Abstract][Full Text] [Related]
30. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
Golob N; Grahek R; Ross M; Roškar R
Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
[TBL] [Abstract][Full Text] [Related]
31. (NDMA) METFORMIN AND (NTTP) SITAGLIPTIN INDUCED CUTANEOUS MELANOMAS: LINKS TO NITROSOGENESIS, NITROSO-PHOTOCARCINOGENESIS, ONCOPHARMACOGENESIS AND THE METABOLIC REPROGRAMMING.
Tchernev G; Broshtilova V
Georgian Med News; 2024 Mar; (348):132-143. PubMed ID: 38807407
[TBL] [Abstract][Full Text] [Related]
32. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
33. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
34. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
[TBL] [Abstract][Full Text] [Related]
35. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
36. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
[TBL] [Abstract][Full Text] [Related]
37. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
Chakravarti S
Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
[TBL] [Abstract][Full Text] [Related]
38. NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CANCERS: ADVANCEMENT ROTATION FLAP FOR KERATOACANTHOMA OF THE UPPER LIP AND UNDERMINING SURGERY FOR BCC OF THE SHOULDER AS AN OPTIMAL DERMATOSURGICAL APPROACH.
Tchernev G
Georgian Med News; 2023 Sep; (342):152-155. PubMed ID: 37991972
[TBL] [Abstract][Full Text] [Related]
39. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
[TBL] [Abstract][Full Text] [Related]
40. PERIOCULAR HIGH RISK BCCS AFTER ADDITIONAL/PARALLEL INTAKE OF TORASEMIDE, MOXONIDINE AND MIRABEGRON: IMPORTANT LINKS TO SKIN CANCER RELATED (PHOTO-) NITROSOGENESIS IN THE CONTEXT OF PHARMACO-ONCOGENESIS.
Tchernev G; Dimova D
Georgian Med News; 2024 Feb; (347):70-76. PubMed ID: 38609117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
